Lipocine【LPCN】株式ニュース

名称	銘柄コード	市場	種別
Lipocine Inc	LPCN	NASDAQ	普通株式

	前日比	前日比 %	現在値	時刻
	0.03	0.46%	6.60	06:33:18

始値	安値	高値	終値	前日終値
6.59	6.4604	6.74	6.60	6.57

この銘柄の詳細情報 »

最新ニュース

日付	時間	ソース	タイトル
2024/5/09	21:00	PRNUS	Lipocine Announces Financial Results for the First Quarter..
2024/5/09	19:06	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/09	19:03	EDGAR2	Form 8-K - Current report
2024/5/08	21:00	PRNUS	Lipocine Announces Late Breaking Oral Presentation of Data..
2024/5/08	19:15	EDGAR2	Form 8-K - Current report
2024/5/01	21:00	PRNUS	Lipocine Announces Completion of Dosing in Pivotal Study of..
2024/4/11	20:00	PRNUS	Lipocine Announces Positive LPCN 2401 Clinical Results..
2024/3/28	21:00	PRNUS	Lipocine Announces Positive Week 52 Results from LPCN 1148..
2024/3/25	21:00	PRNUS	Lipocine Announces First Cohort Dosed in Pivotal Study of..
2024/3/08	07:31	EDGAR2	Form 8-K - Current report
2024/3/07	22:00	PRNUS	Lipocine Announces Financial Results for the Full Year Ended..
2024/3/07	20:08	EDGAR2	Form 8-K - Current report
2024/3/07	20:07	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/3/06	22:00	PRNUS	Lipocine to Present at 36th Annual Roth Conference
2024/3/06	20:01	EDGAR2	Form 8-K - Current report
2024/2/13	06:10	EDGAR2	Form 8-K - Current report
2024/2/06	22:00	PRNUS	Lipocine Announces Confirmation of Dosing Regimen for..
2024/2/02	22:00	PRNUS	Lipocine Announces Continued Commercialization of TLANDO®..
2024/1/18	22:20	EDGAR2	Form 8-K - Current report
2024/1/18	22:00	PRNUS	Lipocine and Verity Pharma Enter into License Agreement for..
2023/12/20	00:00	EDGAR2	Form 8-K - Current report
2023/12/19	22:00	PRNUS	Lipocine to Present at Biotech Showcase 2024
2023/11/23	06:15	EDGAR2	Form S-3 - Registration statement under Securities Act of..
2023/11/14	04:45	EDGAR2	Form 8-K - Current report
2023/11/14	04:45	PRNUS	Lipocine Releases Late Breaking Presentation on LPCN 1148..
2023/11/09	03:15	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/08	23:50	EDGAR2	Form 8-K - Current report
2023/11/08	22:00	PRNUS	Lipocine Announces Financial Results for the Third Quarter..
2023/11/01	22:31	EDGAR2	Form 8-K - Current report
2023/11/01	21:00	PRNUS	Lipocine to Present Clinical Data on LPCN 1148 at The Liver..
2023/10/26	22:35	EDGAR2	Form 8-K - Current report
2023/10/26	21:00	PRNUS	Lipocine Completes Successful Meeting with FDA on LPCN 1154..
2023/10/24	08:00	PRNUS	Lipocine to Present at the H.C. Wainwright Annual NASH..
2023/10/07	05:05	EDGAR2	Form 8-K - Current report
2023/9/20	05:10	EDGAR2	Form 8-K - Current report
2023/9/20	05:05	PRNUS	Lipocine to Present at the Cantor Fitzgerald Global..
2023/8/10	21:35	EDGAR2	Form 8-K - Current report
2023/8/10	21:31	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/10	21:00	PRNUS	Lipocine Announces Financial Results for the Second Quarter..
2023/7/27	19:45	EDGAR2	Form 8-K - Current report
2023/7/27	19:30	PRNUS	LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients..
2023/6/14	21:00	PRNUS	Lipocine to Present at H.C. Wainwright Annual..
2023/6/07	21:00	PRNUS	Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL..